Market Research Logo

Global Acquired Orphan Blood Diseases Therapeutics Market 2015-2019

Global Acquired Orphan Blood Diseases Therapeutics Market 2015-2019

About Acquired Orphan Blood Diseases Therapeutics

Acquired orphan blood diseases are rare disorders and are characterized by the body's inability to produce a sufficient amount of RBCs. This is basically because of the improper functioning of bone marrow to produce RBCs in the blood. This leads to a decrease in platelet counts, which can eventually lead to anemia and thrombosis. The acquired orphan blood diseases are developed in the blood after the post fetal life; they are not caused because of genetic reasons. The major orphan blood diseases that contribute to acquired orphan blood diseases are the following: ITP, MDS, MF PNH, and PV.

TechNavio's analysts forecast the Global Acquired Orphan Blood Diseases Therapeutics market to grow at a CAGR of 12.29 percent over the period 2014-2019.

Covered in this Report

This report covers the present scenario and the growth prospects of the Global Acquired Orphan Blood Diseases Therapeutics market for the period 2015-2019. To calculate the market size, the report considers revenue generated through the sale of marketed drugs used in the treatment of PNH, ITP, PV, MF, and MDS.

TechNavio's report, the Global Acquired Orphan Blood Diseases Therapeutics Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the APAC and EMEA regions; it also covers the Global Acquired Orphan Blood Diseases Therapeutics market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key Regions

  • Americas
  • APAC
  • EMEA
Key Vendors
  • Alexion Pharmaceuticals
  • Amgen
  • Celgene
  • F. Hoffmann- La Roche
  • GlaxoSmithKline
  • Incyte
Other Prominent Vendors
  • Cyclacel Pharmaceuticals
  • CTI Biopharma (Cell Therapeutics)
  • Eli Lilly
  • Gilead Sciences
  • Onconova Therapeutics
  • MebVax Therapeutics
  • Novartis
  • Sanofi
  • Shire Pharmaceuticals
  • S* Bio Pte
Market Driver
  • Exemption from Pricing Obstacle
  • For a full, detailed list, view our report
Market Challenge
  • Companies Hesitant to Invest in Rare Diseases Therapeutics
  • For a full, detailed list, view our report
Market Trend
  • Benefit from Untapped Market
  • For a full, detailed list, view our report
Key Questions Answered in this Report
  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


Press Release

TechNavio Announces the Publication of its Research Report – Global Acquired Orphan Blood Diseases Therapeutics Market 2015-2019

TechNavio recognizes the following companies as the key players in the Global Acquired Orphan Blood Diseases Therapeutics Market: Alexion Pharmaceuticals, Amgen plc, Celgene Corp., F. Hoffmann-La Roche Ltd., GlaxoSmithKline and Incyte Corp.

Other Prominent Vendors in the market are: CTI BioPharma (Cell Therapeutics), Cyclacel Pharmaceuticals, Eli Lilly, Gilead Sciences, MabVax Therapeutics, Novartis, Onconova Therapeutics, Sanofi, Shire Pharmaceuticals and S* Bio.

Commenting on the report, an analyst from TechNavio’s team said: “Entry into untapped markets is one of the major trends upcoming in the market. Currently, the market in many geographical locations remains untapped and provides immense opportunities for vendors to invest in the same. Companies that are pioneers in the development of drugs for acquired orphan blood diseases target physicians who prescribe patients these drugs instead of surgeries and chemotherapy. This has helped manufacturers to increase their product price.”

According to the report, patients diagnosed with acquired orphan blood diseases mostly rely on generics for the treatment. Side effects of these drugs are high and the treatment regimen requires high level of commitment from patients such as regular hospital visits and checkups.

Further, the report states that most pharmaceutical and biotech companies invest extensively in the development of novel drugs to treat rare diseases. However, when marketing and distribution of drugs to potential consumers is taken into consideration, companies are hesitant to invest for the same. Low prevalence of orphan diseases makes it difficult for companies to locate the target population.

Companies Mentioned

Alexion Pharmaceuticals, Amgen, Celgene, F. Hoffmann- La Roche, GlaxoSmithKline, Incyte , Cyclacel  Pharmaceuticals, CTI Biopharma (Cell Therapeutics), Eli Lilly, GileadSciences, Onconova Therapeutics, MebVax Therapeutics, Novartis, Sanofi, Shire Pharmaceuticals, S* Bio Pte 

  • Executive Summary
  • List of Abbreviations
  • Scope of the Report
    • Market Overview
    • Product Offerings
  • Product Profiles
    • Soliris
    • Nplate
    • Revlimid
    • Vidaza
    • Promacta
    • Jakafi
    • Rituxan
  • Market Research Methodology
    • Market Research Process
    • Research Methodology
      • Table Market Research Methodology
  • Introduction
  • Diseases Overview
    • ITP
      • Understanding the Disease
      • Epidemiology
      • Etiology
      • Pathophysiology
      • Management of Disease
        • Table Snapshot of ITP
    • MDS
      • Understanding the Disease
      • Epidemiology
      • Etiology
      • Pathophysiology
      • Management of Disease
        • Table Snapshot of MDS
    • MF
      • Understanding the Disease
      • Epidemiology
      • Etiology
      • Pathophysiology
      • Management of Disease
        • Table Snapshot of MF
    • PNH
      • Understanding the Disease
      • Epidemiology
      • Etiology
      • Pathophysiology
      • Management of Disease
        • Table Snapshot of PNH
    • PV
      • Understanding the Disease
      • Epidemiology
      • Etiology
      • Pathophysiology
      • Management of Disease
        • Table Snapshot of PV
    • Pipeline Analysis
    • Emerging Treatment Options
  • Market Landscape
    • Market Overview
    • Market Size and Forecast
      • Table Global Acquired Orphan Blood Diseases Therapeutics Market 2014-2019 (US$ million)
    • Five Forces Analysis
  • Market Segmentation by Indication Type
    • Table Segmentation of Global Acquired Orphan Blood Diseases Therapeutics Market by Indication Type
    • Table Revenue Comparison of Global Acquired Orphan Blood Diseases Therapeutics Market by Indication Type 2014 and 2019 (US$ million)
    • Table Percent Share of Global Acquired Orphan Blood Diseases Therapeutics Market by Indication Type 2014 and 2019
    • Global ITP Therapeutics Market
      • Market Size and Forecast
        • Table Global ITP Therapeutics Market 2014-2019 (US$ million)
    • Global MDS Therapeutics Market
      • Market Size and Forecast
        • Table Global MDS Therapeutics Market 2014-2019 (US$ million)
    • Global MF Therapeutics Market
      • Market Size and Forecast
        • Table Global MF Therapeutics Market 2014-2019 (US$ million)
    • Global PNH Therapeutics Market
      • Market Size and Forecast
        • Table Global PNH Therapeutics Market 2014-2019 (US$ million)
    • Global PV Therapeutics Market
      • Market Size and Forecast
        • Table Global PV Therapeutics Market 2014-2019 (US$ million)
  • Geographical Segmentation
    • Table Segmentation of Global Acquired Orphan Blood Diseases Therapeutics Market by Geography 2014
  • Buying Criteria
  • Market Growth Drivers
  • Drivers and their Impact
  • Market Challenges
  • Impact of Drivers and Challenges
  • Market Trends
  • Trends and their Impact
  • Vendor Landscape
    • Competitive Scenario
      • Key News
      • Mergers and Acquisitions
    • Market Share Analysis 2014
      • Competitive Assessment of Top Drugs
        • Table Marketing Exclusivity of Orphan Drugs in Some Regions
        • Table Revenue Comparison of Top Drugs 2013 (US$ million)
      • F. Hoffmann-La Roche
        • Table Rituxan: Revenue Comparison 2012 and 2013 (US$ million)
      • Celgene
        • Table Revlimid: Revenue Comparison and YoY Growth 2011-2013 (US$ million)
        • Table Vidaza: Revenue Comparison and YoY Growth 2011-2013 (US$ million)
      • Alexion Pharmaceuticals
        • Table Soliris: Revenue Comparison and YoY Growth 2012-2014 (US$ million)
        • Table Global Acquired Orphan Blood Diseases Therapeutics Market for Soliris 2014-2019 (US$ million)
      • Amgen
        • Table Nplate: Revenue Comparison and YoY Growth 2011-2013 (US$ million)
      • Incyte
        • Table Jakafi: Revenue Comparison 2012 and 2013 (US$ million)
      • GlaxoSmithKline
        • Table Promacta: Revenue Comparison and YoY Growth 2011-2014 (US$ million)
    • Other Prominent Vendors
  • Key Vendor Analysis
    • Amgen
      • Key Facts
      • Business Overview
      • Business Segmentation by Revenue 2013
        • Table Amgen: Business Segmentation by Revenue 2013
      • Product Portfolio by Revenue 2013
        • Table Amgen: Product Portfolio by Revenue 2013
      • Business Segmentation by Revenue 2012 and 2013
        • Table Amgen: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
      • Geographical Segmentation by Revenue 2013
        • Table Amgen: Geographical Segmentation by Revenue 2013
      • Business Strategy
      • Recent Developments
      • SWOT Analysis
    • Alexion
      • Key Facts
      • Business Overview
      • Geographical Segmentation by Revenue 2013
        • Table Alexion: Geographical Segmentation by Revenue 2013
      • Business Strategy
      • Recent Developments
      • SWOT Analysis
    • Celgene
      • Key Facts
      • Business Overview
      • Business Strategy
      • Business Segmentation by Revenue
        • Table Celgene: Business Segmentation by Revenue 2011-2013 (US$ million)
      • Sales by Geography
        • Table Celgene: Sales by Geography 2013
      • Key Information
      • SWOT Analysis
    • F. Hoffmann-La Roche Ltd.
      • Key Facts
      • Business Overview
      • Business Segmentation
        • Table Business Segmentation of F. Hoffmann-La Roche Ltd. 2013
      • Business Segmentation by Revenue 2012 and 2013
        • Table F. Hoffmann-La Roche Ltd.: Business Segmentation by Revenue 2012 and 2013
      • Sales by Geography
        • Table F. Hoffmann-La Roche Ltd.: Sales by Geography 2013 (Pharmaceuticals Division)
        • Table F. Hoffmann-La Roche Ltd.: Sales by Geography 2013 (Diagnostics Division)
      • Business Strategy
      • Key Information
      • SWOT Analysis
    • GlaxoSmithKline
      • Key Facts
      • Business Overview
      • Business Segmentation
        • Table GlaxoSmithKline: Business Segmentation 2013
      • Business Segmentation by Revenue 2012 and 2013
        • Table GlaxoSmithKline: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
      • Sales by Geography
        • Table GlaxoSmithKline: Sales by Geography 2013
      • Pipeline Products
        • Table GlaxoSmithKline: Pipeline Products 2013
      • Business Strategy
      • Key Information
      • SWOT Analysis
      • Strengths
      • Weaknesses
      • Opportunities
      • Threats
    • Incyte
      • Key Facts
      • Business Overview
      • Revenue Segmentation by 2013
        • Table Incyte Corporation: Revenue Segmentation by 2013 (US$ million)
      • Revenue Segmentation by 2012 and 2013
        • Table Incyte Corporation: Revenue Segmentation by 2012 and 2013 (US$ million)
      • Geographical Segmentation
        • Table Incyte Corporation: Geographical Segmentation
      • Business Strategy
      • Recent Developments
      • SWOT Analysis
  • Other Reports in this Series

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report